Last Updated: November 8, 2026

Patent: 10,933,184

Summary for Patent: 10,933,184

Title:	Dialysate free artificial kidney device
Abstract:	A device and method are described for the treatment of blood, which device may be used in conjunction with or in place of a failed Kidney. The device includes an ultrafiltration unit to remove proteins, red and white blood cells and other high molecular weight components, a nanofiltration unit to remove glucose, at least one electrodeionization unit to transport ions from the blood stream, and a reverse osmosis unit to modulate the flow of water, to both the blood and urine streams. In one embodiment, a specialized electrodeionization unit is provided having multiple chambers defining multiple dilute fluid channels, each channel filled with an ion specific resin wafer, and electrodes at the extremity of the device and proximate each of the resin filled dilute channels. By selective application of voltages to these electrodes, the ion transport functionality of a given dilute channel can be turned on or off.
Inventor(s):	Jamie Allen Hestekin, Christa Noel Hestekin, Grace Ann C. Morrison, Sadia Ali Paracha
Assignee:	Us Kidney Research Corp
Application Number:	US15/732,169
Patent Claims:	see list of patent claims

Details for Patent 10,933,184

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 18, 2014	10,933,184	2037-09-27
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 4, 2020	10,933,184	2037-09-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,933,184

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2018341989	⤷ Start Trial
Canada	3075453	⤷ Start Trial
China	111629813	⤷ Start Trial
European Patent Office	3687670	⤷ Start Trial
Spain	2959288	⤷ Start Trial
Japan	2020535014	⤷ Start Trial
Japan	2022048241	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.